Details of the Drug Reposition

General Information of This Drug (ID: DM6XFHS)

Drug Name
SPI-1005   DM6XFHS
Synonyms
Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520
Therapeutic Class
Fibrinolytic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2b Indication(s)
Indication Name Indication ID ICD-11 Status REF
Meniere disease DISC5R5F AB31.0 Phase 2b [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Investigative [2]
------------------------------------------------------------------------------------

References

1 Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial. Jun 25, 2019
2 Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.